|
|
|
51-200 employees
View all
|
|
Biotechnology
|
|
Amryt is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases.
Our CEO Joe Wiley is a doctor by training with a deep interest in rare and debilitating diseases, who felt compelled to do something to transform the lives of patients living with these conditions. Joe gathered a team of experts, all with two things in common - experience in rare diseases and a passion to provide much-needed treatment options for these patients, and that's where Amryt Pharma started in 2015. Since then, we have acquired 3 companies, we now commercialise 3 products and have helped thousands of patients with rare, and debilitating diseases.
Amryt Pharma's online communities are open to the public. Anything posted to our social networks may be seen and read by everyone. We cannot be responsible for views expressed other than our own. By posting on Amryt Pharma's social media pages, you grant us the right to use or reproduce your content.
We welcome questions and commentary, including constructive feedback and differing opinions, but please remember to be both relevant and respectful with what you post. We do not tolerate harassment, abuse, or threats to others. We reserve the right to remove any posts that don’t adhere to our guidelines and to block anyone who violates them repeatedly.
Learn more about our community guidelines here:
https://amrytpharma.com/social-media-guidelines/
|
Amryt Pharma Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Amryt Pharma email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Amryt Pharma customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.